The Latest Breaking News from Moderna

Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.

Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

The shot had previously been approved for everyone 12 and older. Now, there are limits.

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it

The Trump administration said the move signals a ‘shift in federal vaccine funding priorities’

Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding.